Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Translation01:31

Translation

162.2K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
162.2K
Translation01:31

Translation

22.8K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
22.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Initiation of Translation02:33

Initiation of Translation

40.5K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
40.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology.

Annals of surgical oncology·2026
Same author

Clinicogenomic analysis of <i>EGFR</i>-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.

Science translational medicine·2026
Same author

Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer.

Cell reports·2026
Same author

Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology.

Annals of surgical oncology·2026
Same author

Propensity-Adjusted Analysis Evaluating Early Discharge Within 2 Days After Gender-Affirming Vaginoplasty: Insights From a Decade-Long National Surgical Quality Improvement Database.

Annals of plastic surgery·2026
Same author

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal for immunotherapy of cancer·2026
Same journal

Reduced peroxisomal function increases insulin secretion, promotes insulin oxidation, and impairs β cell maturity.

JCI insight·2026
Same journal

De novo VPS16 missense variant causes infantile-onset dystonia with defective autophagic flux.

JCI insight·2026
Same journal

A distinct form of fat fibrosis is linked to insulin resistance in people with HIV.

JCI insight·2026
Same journal

Constitutive YAP activation in distal nephron segments disrupts epithelial identity and nephron patterning.

JCI insight·2026
Same journal

The molecular similarity landscape of preclinical cancer models to patient tumors.

JCI insight·2026
Same journal

A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma.

JCI insight·2026
See all related articles

Related Experiment Video

Updated: Apr 9, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K

Targeting eIF4A-dependent translation in genetically complex sarcoma.

Young-Mi Kim1,2,3, Prathibha Mohan4, Urmila Sehrawat4

  • 1Sarcoma Biology Laboratory.

JCI Insight
|April 7, 2026
PubMed
Summary
This summary is machine-generated.

Targeting the RNA helicase eIF4A effectively suppressed growth and induced apoptosis in deadly sarcomas like dedifferentiated liposarcoma. This approach inhibits translation of key oncogenic factors YAP and TAZ, offering a new therapeutic strategy.

Keywords:
Cell biologyOncogenesOncologyTranslation

More Related Videos

Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

925

Related Experiment Videos

Last Updated: Apr 9, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K
Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

925

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Dedifferentiated liposarcoma (DDLS), myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma (UPS) are genetically complex and deadly sarcomas.
  • Existing treatments lack efficacy, necessitating novel therapeutic strategies.
  • These sarcomas share PI3K/Akt/mTOR and MAPK pathway activation, which are regulated by translation mediated by RNA helicase eIF4A.

Purpose of the Study:

  • To investigate eIF4A inhibition as a targeted therapeutic strategy for DDLS, MFS, and UPS.
  • To identify downstream targets of eIF4A involved in sarcoma progression.
  • To explore the role of the Hippo pathway in these sarcoma types.

Main Methods:

  • Utilized an eIF4A inhibitor (CR-1-31B) in patient-derived cell lines and mouse xenografts.
  • Performed transcriptome-scale ribosome footprinting to identify eIF4A-dependent mRNAs.
  • Conducted gene knockdown and ectopic expression studies for YAP and TAZ.
  • Analyzed genomic data from patient tumors for YAP and WWTR1 alterations.

Main Results:

  • CR-1-31B suppressed tumor growth and induced apoptosis in DDLS, MFS, and UPS models.
  • Identified YAP and TAZ as eIF4A-dependent mRNAs.
  • Combined knockdown of YAP and TAZ induced apoptosis; their ectopic expression conferred partial resistance to CR-1-31B.
  • YAP and WWTR1 amplification/gain in patient tumors correlated with worse clinical outcomes.

Conclusions:

  • eIF4A inhibition is a promising therapeutic strategy for advanced sarcomas.
  • Targeting eIF4A disrupts the translation of oncogenic transcription factors YAP and TAZ.
  • This study identifies a novel therapeutic avenue targeting the Hippo pathway in incurable sarcomas.